A double-blind clinical study comparing the safety and efficacy of Hexabrix and Renografin-76 in contrast enhanced computed body tomography.
Hexabrix, a new low osmolality, iodinated contrast medium and the ionic diatrizoate Renografin-76 were studied in a double-blind parallel group comparison to examine safety and efficacy in patients undergoing contrast assisted CT of the liver, spleen and kidney. No significant differences in pulse, respiration and blood pressure before and after injection were noted in the 100 patients studied. Heat sensation in the Hexabrix group was distinctly lower than in those receiving Renografin, but the two groups did not differ with respect to average scores for pain. There was no difference in adverse side effects. Clinical laboratory studies between the groups showed some differences which could not be attributed to the individual contrast agents. While scan quality of both agents was good to excellent, it should be noted that the dose of Hexabrix was not adjusted to compensate for the difference in iodine content (320 mg I/ml vs. 370 mg I/ml for Renografin-76).
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D003973:Diatrizoate / Q000009:adverse effects / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D012119:Respiration / Q000187:drug effects; D014057:Tomography, X-Ray Computed / Q000009:adverse effects; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D004338:Drug Combinations; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D007485:Ioxaglic Acid